BR112012021291A2 - inibidores diméricos de iap. - Google Patents
inibidores diméricos de iap.Info
- Publication number
- BR112012021291A2 BR112012021291A2 BR112012021291A BR112012021291A BR112012021291A2 BR 112012021291 A2 BR112012021291 A2 BR 112012021291A2 BR 112012021291 A BR112012021291 A BR 112012021291A BR 112012021291 A BR112012021291 A BR 112012021291A BR 112012021291 A2 BR112012021291 A2 BR 112012021291A2
- Authority
- BR
- Brazil
- Prior art keywords
- iap
- dimeric
- dimeric inhibitors
- inhibitors
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30811410P | 2010-02-25 | 2010-02-25 | |
| US33392710P | 2010-05-12 | 2010-05-12 | |
| US38841010P | 2010-09-30 | 2010-09-30 | |
| PCT/EP2011/052662 WO2011104266A1 (en) | 2010-02-25 | 2011-02-23 | Dimeric iap inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012021291A2 true BR112012021291A2 (pt) | 2016-10-25 |
Family
ID=44476672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021291A BR112012021291A2 (pt) | 2010-02-25 | 2011-02-23 | inibidores diméricos de iap. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8445440B2 (enExample) |
| EP (1) | EP2539333A1 (enExample) |
| JP (1) | JP2013520466A (enExample) |
| KR (1) | KR20130010894A (enExample) |
| CN (1) | CN102834389A (enExample) |
| AR (1) | AR080253A1 (enExample) |
| BR (1) | BR112012021291A2 (enExample) |
| CA (1) | CA2790302A1 (enExample) |
| EA (1) | EA201201177A1 (enExample) |
| MX (1) | MX2012009894A (enExample) |
| TW (1) | TW201141846A (enExample) |
| UY (1) | UY33236A (enExample) |
| WO (1) | WO2011104266A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US20140243276A1 (en) | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| EP2882740B1 (en) * | 2012-08-09 | 2017-03-01 | Bristol-Myers Squibb Company | Iap antagonists |
| US20140135270A1 (en) * | 2012-11-09 | 2014-05-15 | Ensemble Therapeutics Corp. | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| SG11201509525XA (en) | 2013-06-25 | 2016-01-28 | Inst Medical W & E Hall | Method of treating intracellular infection |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| CN109705191B (zh) * | 2017-10-25 | 2022-04-29 | 广东东阳光药业有限公司 | Iap抑制剂及其在药物中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US5281620A (en) | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| JP2002037626A (ja) | 2000-07-27 | 2002-02-06 | Internatl Superconductivity Technology Center | ビスマス系高温超電導体の製造方法。 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| JP2006514096A (ja) | 2002-11-27 | 2006-04-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 癌細胞においてアポトーシスを誘導するための方法および組成物 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| CA2552937A1 (en) | 2004-02-05 | 2005-08-18 | Novartis Ag | Combination of (a) a dna topoisomerase inhibitor and (b) an iap inhibitor |
| US7309792B2 (en) * | 2004-03-01 | 2007-12-18 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| CN103083644B (zh) * | 2005-02-25 | 2014-05-28 | 泰特拉洛吉克药业公司 | Iap二聚体抑制剂 |
| EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2617642A1 (en) | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| CA2564872C (en) * | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| AU2006331964A1 (en) * | 2005-12-20 | 2007-07-05 | Novartis Ag | Combination of an IAP-inhibitor and a taxane7 |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| MX2008012053A (es) | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| SG171682A1 (en) | 2006-05-16 | 2011-06-29 | Aegera Therapeutics Inc | Iap bir domain binding compounds |
| AR064235A1 (es) | 2006-07-24 | 2009-03-25 | Tetralogic Pharmaceuticals Cor | Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014238A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| EP2049563B1 (en) | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100144650A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110220A1 (es) * | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| JP2010507096A (ja) * | 2006-10-19 | 2010-03-04 | ノバルティス アーゲー | 有機化合物 |
| WO2008066854A2 (en) | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| KR20090083412A (ko) * | 2006-11-28 | 2009-08-03 | 노파르티스 아게 | 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도 |
| KR101149449B1 (ko) | 2007-03-20 | 2012-05-25 | 삼성전자주식회사 | 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치 |
| CA2684169C (en) * | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
| AU2008245447C1 (en) | 2007-04-30 | 2014-11-20 | Genentech, Inc. | Inhibitors of IAP |
| WO2008137930A1 (en) | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
| JP5658565B2 (ja) | 2007-09-12 | 2015-01-28 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| CN101970457A (zh) | 2008-01-11 | 2011-02-09 | 健泰科生物技术公司 | Iap抑制剂 |
| US20110288116A1 (en) | 2008-01-24 | 2011-11-24 | Tetralogic Pharmaceuitcal Corporation | Iap inhibitors |
| US20110117081A1 (en) | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US20110171171A1 (en) | 2008-06-27 | 2011-07-14 | Aegera Therapeutics, Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
| EP2318395A4 (en) | 2008-08-02 | 2011-10-26 | Genentech Inc | IPA INHIBITORS |
| WO2010015090A1 (en) | 2008-08-07 | 2010-02-11 | Aegera Therapeutics Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US8399683B2 (en) | 2008-09-17 | 2013-03-19 | Tetralogic Pharmaceuticals | IAP inhibitors |
| EP2350641B1 (en) | 2008-09-22 | 2014-09-24 | Amgen Inc. | A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
-
2011
- 2011-02-21 UY UY0001033236A patent/UY33236A/es not_active Application Discontinuation
- 2011-02-23 JP JP2012554332A patent/JP2013520466A/ja active Pending
- 2011-02-23 BR BR112012021291A patent/BR112012021291A2/pt not_active IP Right Cessation
- 2011-02-23 KR KR1020127024875A patent/KR20130010894A/ko not_active Withdrawn
- 2011-02-23 US US13/033,463 patent/US8445440B2/en not_active Expired - Fee Related
- 2011-02-23 EA EA201201177A patent/EA201201177A1/ru unknown
- 2011-02-23 MX MX2012009894A patent/MX2012009894A/es active IP Right Grant
- 2011-02-23 CN CN2011800177078A patent/CN102834389A/zh active Pending
- 2011-02-23 EP EP11705532A patent/EP2539333A1/en not_active Withdrawn
- 2011-02-23 CA CA2790302A patent/CA2790302A1/en not_active Abandoned
- 2011-02-23 AR ARP110100547A patent/AR080253A1/es unknown
- 2011-02-23 WO PCT/EP2011/052662 patent/WO2011104266A1/en not_active Ceased
- 2011-02-24 TW TW100106289A patent/TW201141846A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011104266A1 (en) | 2011-09-01 |
| JP2013520466A (ja) | 2013-06-06 |
| US8445440B2 (en) | 2013-05-21 |
| EP2539333A1 (en) | 2013-01-02 |
| CN102834389A (zh) | 2012-12-19 |
| TW201141846A (en) | 2011-12-01 |
| CA2790302A1 (en) | 2011-09-01 |
| EA201201177A1 (ru) | 2013-04-30 |
| AR080253A1 (es) | 2012-03-21 |
| AU2011219862A1 (en) | 2012-09-06 |
| KR20130010894A (ko) | 2013-01-29 |
| UY33236A (es) | 2011-09-30 |
| US20110206690A1 (en) | 2011-08-25 |
| MX2012009894A (es) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012021291A2 (pt) | inibidores diméricos de iap. | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| BR112014001801A2 (pt) | indazóis | |
| BR112014030795A2 (pt) | composto, composição farmacêutica, uso de um composto e processo para preparação de um composto | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| BR112015010221A2 (pt) | inibidores de cinase alk | |
| CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
| JOP20180103A1 (ar) | مركب صيدلاني | |
| EA201201665A1 (ru) | Новые соединения | |
| EA201391822A1 (ru) | Новые производные пиридина | |
| EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
| EA201491180A1 (ru) | 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с | |
| JO2998B1 (ar) | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان | |
| EA201070988A1 (ru) | Противовирусные терапевтические средства | |
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| BR112012033402A2 (pt) | moduladores de canais de íons conforme os compostos heterocíclicos fundidos | |
| JOP20180104A1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| EA201390381A1 (ru) | Триазиноксадиазолы | |
| MD4556B1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |